ストックスクリーナーアプリを入手
58.22
14.63%
-9.98
アフターアワーズ：
58.24
0.02
+0.03%
前日終値:
$68.20
開ける：
$59.19
24時間の取引高:
26.55M
Relative Volume:
4.92
時価総額：
$22.83B
収益：
$4.30B
当期純損益:
$571.50M
株価収益率:
40.76
EPS:
1.4285
ネットキャッシュフロー:
$570.80M
1週間 パフォーマンス:
-17.22%
1か月 パフォーマンス:
-13.48%
6か月 パフォーマンス:
-18.44%
1年 パフォーマンス:
-17.40%
1日の値動き範囲:
$56.45
$60.36
1週間の範囲:
$56.45
$71.11
52週間の値動き範囲:
$56.45
$93.25
Dexcom Inc Stock (DXCM) Company Profile
DXCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
58.22 | 26.74B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
123.62 | 216.79B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.72 | 149.02B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
356.24 | 141.06B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
90.70 | 116.68B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.45 | 49.01B | 5.69B | 1.41B | 577.90M | 1.8485 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 再開されました | Stifel | Buy |
| 2025-09-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 開始されました | Argus | Buy |
| 2025-06-16 | 開始されました | Truist | Buy |
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
DexCom (NASDAQ:DXCM) Price Target Lowered to $75.00 at JPMorgan Chase & Co. - MarketBeat
What catalysts could drive DexCom Inc. stock higherWeekly Loss Report & Precise Swing Trade Entry Alerts - newser.com
Will DexCom Inc. stock maintain momentum in 2025Weekly Profit Recap & Smart Allocation Stock Tips - newser.com
DexCom (DXCM): Net Margin Slides to 13.3%, Testing Bulls’ Profitability Narratives - Yahoo Finance
Class Action Announcement for DexCom, Inc. (DXCM): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against DexCom, Inc. - GlobeNewswire Inc.
Royal Bank Of Canada Cuts DexCom (NASDAQ:DXCM) Price Target to $85.00 - MarketBeat
DexCom (NASDAQ:DXCM) Shares Gap Down After Analyst Downgrade - MarketBeat
DexCom (NASDAQ:DXCM) Price Target Lowered to $85.00 at BTIG Research - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Q3 2025 Earnings Call Transcript - Insider Monkey
Fisher Funds Management LTD Sells 339,084 Shares of DexCom, Inc. $DXCM - MarketBeat
Hantz Financial Services Inc. Trims Stake in DexCom, Inc. $DXCM - MarketBeat
Envestnet Asset Management Inc. Increases Stock Position in DexCom, Inc. $DXCM - MarketBeat
What MACD trends signal for DexCom Inc. (DC4) stockQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
JP Morgan Maintains DexCom (DXCM) Neutral Recommendation - Nasdaq
Dexcom’s revenue is up, but sensor scrap issue hit margins - Modern Healthcare
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
DexCom (NASDAQ:DXCM) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
DexCom (DXCM): Canaccord Genuity Lowers Price Target to $99.00 | - GuruFocus
DexCom (DXCM): Citigroup Lowers Price Target to $75 while Mainta - GuruFocus
Halloween turns scary for Dexcom despite strong Q3 - BioWorld MedTech
S&P 500 Gains and Losses Today: Amazon Stock Surges as Cloud Business Boosts Earnings; DexCom Drops - Investopedia
Amazon Jumps, First Solar Shines, DexCom Drops In Busy Quarter - Finimize
JP Morgan Lowers Price Target for DexCom (DXCM) to $75, Maintain - GuruFocus
DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised - sharewise.com
Why DexCom Stock Is Crashing Today - sharewise.com
DexCom (DXCM) Shares Drop Despite Strong Q3 Results and Revenue Guidance Boost - GuruFocus
DexCom’s Shares Drop Despite Beating Earnings Expectations - Finimize
Why DexCom (DXCM) Stock Is Falling Today - Yahoo Finance
DXCM Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc. - The AI Journal
Traders Purchase High Volume of DexCom Call Options (NASDAQ:DXCM) - MarketBeat
Shareholders who lost money in shares of DexCom, Inc. - GlobeNewswire
DexCom slips after earnings on margin trends, 2026 growth concerns - Seeking Alpha
DexCom stock hits 52-week low at 57.5 USD By Investing.com - Investing.com Nigeria
DexCom stock hits 52-week low at 57.5 USD - Investing.com
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); DexCom, Inc. (NASDAQ: ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Avantor, Inc. - GlobeNewswire
Dexcom execs say company has fixed G7 quality problems - MedTech Dive
DexCom Stock Is the Worst Performer in the S&P 500. Here’s Why. - Barron's
Dexcom shares extend fall over 2026 growth concerns - TradingView
Wells Fargo Adjusts Price Target on DexCom to $93 From $98 - MarketScreener
Citigroup Adjusts Price Target on DexCom to $75 From $85 - MarketScreener
Bernstein Adjusts Price Target on DexCom to $84 From $98 - MarketScreener
Goldman Sachs Adjusts Price Target on DexCom to $83 From $89 - MarketScreener
Leerink Partners Adjusts Price Target on DexCom to $81 From $101 - MarketScreener
RBC Cuts Price Target on DexCom to $85 From $100, Keeps Outperform Rating - MarketScreener
BTIG Adjusts Price Target on DexCom to $85 From $109 - MarketScreener
TD Cowen Adjusts Price Target on DexCom to $84 From $100 - MarketScreener
Raymond James Adjusts Price Target on DexCom to $83 From $102 - MarketScreener
Dexcom Shares Take A Hit As 2026 Guidance Disappoints - Finimize
Is DexCom Inc. stock attractive for passive investorsQuarterly Profit Review & Real-Time Stock Entry Alerts - newser.com
Will breakout in DexCom Inc. lead to full recovery2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
0.34%
大文字化:
|
ボリューム (24 時間):